Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Patients With Metastatic Castration-resistant Prostate Cancer”

612 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 612 results

Testing effectiveness (Phase 2)Study completedNCT00151073
What this trial is testing

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Who this might be right for
Hormone-Refractory Prostate Cancer
University of Michigan Rogel Cancer Center 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06500247
What this trial is testing

Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.

Who this might be right for
The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Qilu Hospital of Shandong University 43
Not applicableStudy completedNCT03896984
What this trial is testing

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer 346
Testing effectiveness (Phase 2)Study completedNCT00323882
What this trial is testing

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate CancerNeoplasm Metastasis
Bristol-Myers Squibb 75
Early research (Phase 1)Study completedNCT03076203
What this trial is testing

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Who this might be right for
Prostate Carcinoma Metastatic to the BoneStage IV Prostate AdenocarcinomaHormone-refractory Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 14
Testing effectiveness (Phase 2)Study completedNCT04060394
What this trial is testing

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Laekna Limited 49
Early research (Phase 1)Study completedNCT03024216
What this trial is testing

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
University of Hawaii 37
Testing effectiveness (Phase 2)Study completedNCT02952534
What this trial is testing

Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 277
Not applicableStudy completedNCT02495974
What this trial is testing

European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Astellas Pharma Europe Ltd. 1,763
Large-scale testing (Phase 3)Study completedNCT01695135
What this trial is testing

Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Who this might be right for
Prostate Neoplasms
Janssen Research & Development, LLC 214
Testing effectiveness (Phase 2)Study completedNCT00887458
What this trial is testing

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Who this might be right for
Prostate Cancer
Johns Hopkins University 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT01688492
What this trial is testing

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 54
Early research (Phase 1)Looking for participantsNCT07219147
What this trial is testing

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
City of Hope Medical Center 30
Early research (Phase 1)Active Not RecruitingNCT03874884
What this trial is testing

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Peter MacCallum Cancer Centre, Australia 70
Post-approval studies (Phase 4)Study completedNCT01649635
What this trial is testing

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 45
Not applicableStudy completedNCT00636090
What this trial is testing

Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Duke University 35
Post-approval studies (Phase 4)Study completedNCT02485691
What this trial is testing

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Who this might be right for
Prostate Cancer Metastatic
Sanofi 255
Testing effectiveness (Phase 2)Ended earlyNCT04754425
What this trial is testing

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaCastration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted AgentsMetastatic Malignant Neoplasm in the Bone+5 more
M.D. Anderson Cancer Center 11
Early research (Phase 1)UnknownNCT04839991
What this trial is testing

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Who this might be right for
Advanced and/or Metastatic Solid Tumours
Crescendo Biologics Ltd. 70
Not applicableEnded earlyNCT02370355
What this trial is testing

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate Carcinoma
University of Southern California 24
Load More Results